Global Plasmid DNA Manufacturing Market, by Product Type (High Quality (HQ) Plasmid DNA, GMP Grade Plasmid DNA, and Non-GMP Grade Plasmid DNA), by Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 65.1 million in 2017 and is projected to exhibit a CAGR of 23.7% over the forecast period (2018 – 2026), as highlighted in a new report published by .

Increased research and development activity is expected to augment the market growth

Key players in the market are focused on research & development, expansion, and collaboration activities in order to enhance their market share. For instance, in January 2019, Sarepta Therapeutics, Inc. and Aldevron announced their collaboration. This collaboration provided Sarepta with Aldevron’s manufacturing slots and capacity for production of GMP grade plasmid for its various programs related to gene therapy.

For instance, in January 2019, Sarepta Therapeutics, Inc. collaborated with Aldevron to supply GMP grade plasmids, in order to cater to the demand of Sarepta’s gene therapy clinical trials and for commercial supply.

Moreover, in April 2018, PlasmidFactory GmbH & Co. KG announced the acquisition of new laboratory space to expand research and development activities and production of plasmid DNA. This strategic move was taken, owing to increasing demand for High Quality (HQ) Grade DNA production.

Browse 36 Market Data Tables and 32 Figures spread through 149 Pages and in-depth TOC on ‘Plasmid DNA Manufacturing Market’- Global Forecast to 2026, by Product Type (High Quality (HQ) Plasmid DNA, GMP Grade Plasmid DNA, and Non-GMP Grade Plasmid DNA), by Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Plasmid DNA Manufacturing Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/plasmid-dna-manufacturing-market-2593

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in February 2016, Agilis Biotherapeutics, LLC (Agilis) and Waisman Biomanufacturing entered into an exclusive partnership agreement for the production of Agilis’ novel gene therapy product, AGIL-FA, for the treatment of Friedreich’s ataxia (FA).

Similarly, in March 2019, Aldevron announced expansion plan for antibody development platform facility in Germany. This expansion plan will add around 4,300 square feet of production and laboratory space to current facility.

Key Takeaways of the Plasmid DNA Manufacturing Market:

  • The global plasmid DNA manufacturing market is expected to exhibit a CAGR of 23.7% over the forecast period, owing to increasing demand for plasmid (pDNA) DNA
  • Among product type, the high quality plasmid DNA segment held dominant position in the plasmid DNA manufacturing market in 2017, owing to increased usage of higher quality plasmid DNA in biotechnology research and vaccine production
  • Among application, immunotherapy segment held dominant position in the plasmid DNA manufacturing market in 2017, owing to high adoption rate of immunotherapy
  • Key players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: